Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 121

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 121
---
 |     | 2024 |     |        | 475,000 |     |       |      — |    |     |        | — |     |                      | 182,156 |     |                      | 237,500 |     |                 | 75,744 |     |       |   970,400 |
| Chief Operating Officer |     | 2023 |     |        | 425,000 |     |       |      — |    |     |        | — |     |                      |  53,688 |     |                      | 212,500 |     |                 | 78,851 |     |       |   770,039 |
| Roger Waltzman, M.D.    |     | 2024 |     |        | 500,000 |     |       |      — |    |     |        | — |     |                      | 182,156 |     |                      | 200,000 |     |                 | 46,723 |     |       |   928,879 |
| Chief Medical Officer   |     | 2023 |     |        | 196,742 |     |       | 20,000 | -3 |     |        | — |     |                      | 140,811 |     |                      | 196,000 |     |                 | 32,612 |     |       |   586,165 |

(1) The amounts reported do not reflect the amounts actually received by our named executive officers. Instead, in accordance with SEC rules, these amounts reflect the grant date fair value of stock options granted to our named executive officers during the fiscal years ended December 31, 2024 and 2023, as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transaction. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Assumptions used in the calculation of amounts for 2023 are included in Note 6 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 13, 2024. Our named executive officers will only realize compensation with regard to these options to the extent the trading price of our common stock is greater than the exercise price of such options.

(2) For 2024 and 2023, referenced amount is for the